UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The impact of socioeconomic status on access to cancer clinical trials

British journal of cancer, 2014-10, Vol.111 (9), p.1684-1687

2014

Volltextzugriff (PDF)

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

British journal of cancer, 2012-03, Vol.106 (6), p.1100-1106

2012

Volltextzugriff (PDF)

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2012-08, Vol.23 (8), p.2094-2102

2012

Volltextzugriff (PDF)

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer

Current cancer drug targets, 2012-02, Vol.12 (2), p.107-123

2012

Volltextzugriff (PDF)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of oncology, 2019-07, Vol.30 (7), p.1121-1126

2019

Volltextzugriff (PDF)

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Volltextzugriff (PDF)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Annals of oncology, 2018-11, Vol.29 (11), p.2214-2222

2018

Volltextzugriff (PDF)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Annals of oncology, 2019-03, Vol.30 (3), p.447-455

2019

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1421-1427

2015

Volltextzugriff (PDF)

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Annals of oncology, 2021-05, Vol.32 (5), p.620-630

2021

Volltextzugriff (PDF)

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer

Annals of oncology, 2014-02, Vol.25 (2), p.505-511

2014

Volltextzugriff (PDF)

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

Investigational new drugs, 2013-02, Vol.31 (1), p.115-125

2013

Volltextzugriff (PDF)

The epidemiology of self‐poisoning in the UK

British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.613-619

2003

Volltextzugriff (PDF)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

NPJ precision oncology, 2021-10, Vol.5 (1), p.91-91, Article 91

2021

Volltextzugriff (PDF)

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Lung cancer (Amsterdam, Netherlands), 2023-11, Vol.185, p.107376-107376, Article 107376

2023

Volltextzugriff (PDF)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

British journal of cancer, 2008-12, Vol.99 (12), p.1984-1990

2008

Volltextzugriff (PDF)

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data

British journal of cancer, 2006-09, Vol.95 (5), p.649-652

2006

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-10, Vol.29 (10), p.2143-2143

2018

Volltextzugriff (PDF)

Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK

British journal of cancer, 2007-03, Vol.96 (5), p.752-757

2007

Volltextzugriff (PDF)

Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.7-13

2022

Volltextzugriff (PDF)

Realizing the potential of plasma genotyping in an age of genotype-directed therapies

JNCI : Journal of the National Cancer Institute, 2014-08, Vol.106 (8), p.dju214-dju214

2014

Volltextzugriff (PDF)

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2012-07, Vol.70 (1), p.65-74

2012

Volltextzugriff (PDF)

RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial

Annals of oncology, 2018-10, Vol.29, p.viii417-viii417

2018

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(292)
Mit Volltextzugriff
(278)

Publikationsform

Artikel
(293)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(101)
Science & Technology
(99)
Life Sciences & Biomedicine
(98)
Oncology
(85)
Male
(54)
Lung Neoplasms - Drug Therapy
(50)
Middle Aged
(50)
Female
(46)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(41)
Adult
(39)
Aged
(37)
Lung Neoplasms - Pathology
(35)
Biological And Medical Sciences
(28)
Medical Sciences
(27)
Lung Neoplasms - Genetics
(25)
Carcinoma, Non-Small-Cell Lung - Pathology
(24)
Tumors
(24)
Aged, 80 And Over
(22)
Lung Cancer
(22)
Carcinoma, Non-Small-Cell Lung - Genetics
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The impact of socioeconomic status on access to cancer clinical trials

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

The epidemiology of self‐poisoning in the UK

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK

Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

Realizing the potential of plasma genotyping in an age of genotype-directed therapies

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial

Suchergebnisse filtern